Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer Journal Article
| Authors: | Markman, M.; Rothman, R.; Reichman, B.; Hakes, T.; Lewis, J. L. Jr; Rubin, S.; Jones, W.; Almadrones, L.; Hoskins, W. |
| Article Title: | Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer |
| Abstract: | The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following the discontinuation of cisplatin. Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium <1.4 mg/l), including 3 patients with serum magnesium values <1.0 mequiv/l. The median cisplatin-free interval for these 9 patients was 19 months (range 6-40 months). We conclude that persistent, and possibly permanent, hypomagnesemia is common following cisplatin chemotherapy. © 1991 Springer-Verlag. |
| Keywords: | adult; clinical article; retrospective studies; cisplatin; ovarian neoplasms; ovary cancer; time factors; hypomagnesemia; kidney function; intravenous drug administration; magnesium; renal function; human; female; article; support, non-u.s. gov't |
| Journal Title: | Journal of Cancer Research and Clinical Oncology |
| Volume: | 117 |
| Issue: | 2 |
| ISSN: | 0171-5216 |
| Publisher: | Springer |
| Date Published: | 1991-03-01 |
| Start Page: | 89 |
| End Page: | 90 |
| Language: | English |
| DOI: | 10.1007/bf01613129 |
| PUBMED: | 2007614 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 27 September 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work